Single center experience with pre-dialysis patients

• Published in: Saudi journal of kidney diseases and transplantation Vol. 13; no. 3; pp. 363 - 370
• Main Authors: al-Wakil, Jamal S., Tarif, Numan, al-Sulaymani, Fatimah, Isnani, Arthur C., Askar, Akram, Mimun, Nawaz A. H., Abu Ayshah, Hasan, Mutawalli, Ahmad Hassan
• Format: Journal Article
• Language: English
• Published: Riyadh, Saudi Arabia Saudi Center for Organ Transplantation 01-07-2002
• Subjects: Dialysis; Hemodialysis; Patients; الأسموزية; الأمراض; الكلى; المرضى; غسيل الكلى
• ISSN: 1319-2442; 2320-3838

The objective of this study was to evaluate the effect of the management of factors accelerating renal injury such as hypertension and diabetes on progression of chronic renal failure (CRF). For this end, the records of 112 CRF patients with serum creatinine (SCr) level of 150- 850 µmol / L were retrospectively studied at King Khaled University Hospital in Riyadh, Saudi Arabia. The leading causes of CRF in the study patients were diabetes in 52 (46.4%) patients, glomerulonephritis in 25 (22.4%) and hypertension in 17 (15.2%). Progressive elevation of SCr level was recorded at 92 µmol / L / year in 62 (55.4%) patients with initial SCr level of 150-300 µmol / L ; they progressed to end stage renal disease (ESRD) in a mean duration of 4 ½ years. Forty-three (38.4%) patients with SCr level of 300-450 µmol / L had an increase of SCr at 136 µmol / L / year and progressed to ESRD in a mean period of four years. Seven (6.2%) patients who had initial SCr level of > 450 µmol / L had an increase of 136 µmol / L / year and progressed to ESRD in a mean duration of 2 ½ years. Sixty-two (55.4%) patients had initial blood pressure (BP) readings above the recommended level of 130 / 80 mm Hg. Antihypertensive management stabilized 47 (75.8%) of these patients using multiple drug regimens such as an angiotensin converting enzyme (ACE) inhibitor and diuretics (20.5%). Though this center did not use erythropoietin (EPO) in these patients, the control of the levels of hemoglobin and hematocrit was obtained by aggressive iron supplementation including intravenous administration. In conclusion, the present management of CRF patients, which attempts to comply with the international standards, still needs refining in order to reach better outcome.